Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort
American Journal of Clinical Pathology · 02.05.2023 · 159 (5) · 484-491
DOI: 10.1093/ajcp/aqac184 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 28.02.2023. Verfasst von Cansu Karakas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Rochester Medical Center, Rochester, NY, US. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunohistochemistry. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
We assessed the interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low–expressing breast cancer cohort.
Methods
A total of 114 breast cancer specimens were stained by HercepTest (Agilent Dako) and PATHWAY anti-HER2 (4B5) (Ventana) antibody assays and scored by 6 breast pathologists independently using current HER2 guidelines. Level of agreement was evaluated by Cohen κ analysis.
Results
Although the interobserver agreement rate for both antibodies achieved substantial agreement, the average rate of agreement for HercepTest was significantly higher than that for the 4B5 clone (74.3% vs 65.1%; P = .002). The overall interantibody agreement rate between the 2 antibodies was 57.8%. Complete interobserver concordance was achieved in 44.7% of cases by HercepTest and 45.6% of cases by 4B5. Absolute agreement rates increased from HER2 0-1+ cases (78.1% by HercepTest and 72.2% by 4B5; moderate agreement) to 2-3+ cases (91.9% by HercepTest and 86.3% by 4B5; almost perfect agreement).
Conclusions
Our results demonstrated notable interobserver and interantibody variation on evaluating HER2 immunohistochemistry, especially in cases with scores of 0-1+, although the performance was much more improved among breast-specialized pathologists with the awareness of HER2-low concept. More accurate and reproducible methods are needed for selecting patients who may benefit from the newly approved HER2-targeting agent on HER2-low breast cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Rochester Medical Center, Rochester, NY, US.
- Class of 2024, University of Rochester, Rochester, NY, US.
ORCID-Profile: Huina Zhang
Zitieren
APA
Karakas, C., Tyburski, H., Turner, B. M., Wang, X., Schiffhauer, L. M., Katerji, H., Hicks, D. G., & Zhang, H. (2023). Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort. American Journal of Clinical Pathology, 159(5), 484-491. https://doi.org/10.1093/ajcp/aqac184
Vancouver
Karakas C, Tyburski H, Turner BM, Wang X, Schiffhauer LM, Katerji H, et al. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort. American Journal of Clinical Pathology. 2023;159(5):484-491. doi:10.1093/ajcp/aqac184
BibTeX
@article{Karakas2023,
author = {Karakas, Cansu and Tyburski, Haley and Turner, Bradley M and Wang, Xi and Schiffhauer, Linda M and Katerji, Hani and Hicks, David G and Zhang, Huina},
title = {Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort},
journal = {American Journal of Clinical Pathology},
year = {2023},
volume = {159},
number = {5},
pages = {484--491},
doi = {10.1093/ajcp/aqac184}
}
EUVIMED